mRNA expression profiling for Stage T1 bladder cancer subtyping
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Stage T1 bladder cancers have high progression and recurrence rates, and existing treatments like BCG therapy are not effective for all patients, leading to potential aggressive tumor progression and recurrence.
Innovation Solution
The development of methods and systems for diagnosing, staging, stratifying, and treating bladder cancer by generating an mRNA expression profile for Stage T1 bladder cancer and classifying it based on specific gene expression patterns, including detecting regulons, somatic copy numbers, immune scores, and inflammation levels, to identify distinct subtypes such as T1-LumGU, T1-Inflam, T1-Myc, T1-TLum, and T1-Early, which guide personalized treatment approaches.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If BCG therapy is used to treat Stage T1 bladder cancer, then most patients receive standard treatment, but many patients experience tumor progression or recurrence
Solution Approach 1:
The patent segments Stage T1 bladder cancer into five distinct molecular subtypes (T1-LumGU, T1-Inflam, T1-Myc, T1-TLum, T1-Early) based on gene expression profiles. This segmentation allows identification of specific subtypes that respond differently to BCG therapy, enabling personalized treatment decisions rather than uniform treatment for all patients.
Solution Approach 2:
The patent changes the treatment approach parameter from a single standardized BCG therapy to subtype-specific treatment strategies. By analyzing gene expression parameters and identifying molecular subtypes, the system determines whether to administer BCG, recommend cystectomy, or suggest alternative therapies based on the specific molecular characteristics of each patient's tumor.
2Reliability
If aggressive tumors are treated with early cystectomy, then progression is controlled, but treatment intensity increases and may be unnecessarily aggressive for less aggressive tumors
Solution Approach 1:
The patent applies local quality by tailoring treatment aggressiveness to the specific molecular subtype of each patient's tumor. High-risk subtypes (T1-Myc, T1-Early) receive more aggressive interventions like early cystectomy, while lower-risk subtypes receive less aggressive management. This ensures appropriate treatment intensity matched to the actual biological aggressiveness of each tumor type.
3Adaptability or versatility
If molecular subtyping is performed to identify aggressive tumors, then personalized treatment is enabled, but diagnostic complexity and cost increase
Solution Approach 1:
The patent replaces complex surgical pathology assessment with molecular profiling through gene expression analysis. Instead of relying on traditional histological examination which requires extensive surgical intervention and expert pathological review, the system uses transcriptome profiling to identify molecular subtypes, simplifying the diagnostic workflow while enabling more precise subtype classification.
Data Source
AI summary
Disclosed are methods and systems for diagnosing, staging, stratifying, prognosing, and/or treating bladder cancer. In particular, the invention relates to methods and systems for classifying Stage T1 bladder cancer. The disclosed methods may include generating an mRNA expression profile for a sample of Stage T1 bladder cancer and classifying the sample based on the expression profile.